payday loans
payday loans
Skip to content

Accueil Pitfalls in developing new compounds for idiopathic pulmonary fibrosis
Pitfalls in developing new compounds for idiopathic pulmonary fibrosis Imprimer Envoyer
Lundi, 14 Août 2017 07:23
imagePurpose of review: The development and availability of nintedanib and pirfenidone has heralded a new era in the management of idiopathic pulmonary fibrosis (IPF). Both agents demonstrate that the disease can be successfully modulated with therapeutic interventions, but neither are a cure and IPF remains a deadly disease. Recent findings: There have been many lessons about the natural history of IPF and clinical trial design, not only from the clinical development programs for nintedanib and pirfenidone, but also the numerous negative trials that predated these. Summary: In this review, we attempt to synthesize how the field of IPF and clinical trials has evolved, the lessons learnt, and how these might inform and enable more efficient future clinical trial designs that are primed for success.

Author:

Read Full Article
 

find-us-on-facebook-2

United4LungHealth

image001

World Allergy Week 2017 The Agony of Hives

WCOPDday2017



PubMed Logo
Word

 To: 

Langtolang Dictionary

CNP2014Ebook

50x50_firefoxsafari_iconGchrome


Notre site est optimisé pour les Navigateurs suivants : Firefox, Safari et Google Chrome. Cliquez sur l'un des logos ci-dessus pour le télécharger et l'installer gratuitement.

Tabac

Accueil Pitfalls in developing new compounds for idiopathic pulmonary fibrosis Top